Individualizing Pharmacotherapy for African American Smokers
common.study.values.description
“Individualizing Pharmacotherapy for African American Smokers”
Improving cessation outcomes for African American smokers through the use of novel, empirically-based strategies is a national health priority. In the vast majority of smoking cessation studies and in clinical practice, when smokers are provided a medication to help them quit, they are expected to continue that medication regardless of how well it is working. This study will assess whether African Americans smokers respond better if they continue with a single treatment or if their treatment is changed when that treatment is not working.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - Nicotine patch
Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
Drug - Varenicline Tartrate
VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
Drug - Bupropion
BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
participant.views.study.view.additional
participant.views.study.view.scientific-title
Individualizing Pharmacotherapy: A Novel Optimization Strategy to Increase Smoking Cessation in the African American Community
common.study.values.clinical-trial-id
NCT03897439
participant.views.study.view.id
b687ze
